The BECN1 Knockout A2780 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BECN1 gene in A2780 human ovarian carcinoma epithelial cells. This polyclonal product provides a heterogeneous loss-of-function model without clonal isolation, enabling robust pooled functional screens and bulk biochemical analyses that better reflect tumor population diversity. Disruption of BECN1 abolishes Beclin 1 protein expression, a scaffold critical for autophagosome nucleation and class III PI3K complex assembly.
The A2780 line originates from an untreated patient with ovarian endometrioid adenocarcinoma and serves as a well-characterized, drug-sensitive model of epithelial ovarian cancer. These cells retain key oncogenic features and are widely used to study chemosensitivity, tumorigenesis, and apoptosis. Their established relevance in autophagy research provides an ideal background for investigating BECN1-dependent processes, including response to platinum-based therapeutics.
BECN1 encodes Beclin 1, a core component of the class III PI3K complex that nucleates autophagosomes. Beclin 1 integrates signals from upstream kinases ULK1 and AMPK, while being inhibited by mTORC1 and BCL2 binding. Upon activation, it recruits PIK3C3/VPS34 and ATG14 to produce PI3P, driving phagophore formation. Downstream, it controls ATG5, ATG7, LC3B, and SQSTM1/p62, linking autophagy to endocytic trafficking via UVRAG and RUBCN. Furthermore, BECN1??s interaction with AMBRA1 enhances kinase activity, while RUBCN suppresses it, highlighting its regulatory complexity. Thus, BECN1 disruption impairs autophagy flux, lysosomal degradation, and stress responses.
In A2780 cells, BECN1 knockout is highly significant for dissecting autophagy??s dual role in tumor suppression and drug resistance. Beclin 1 is frequently monoallelically lost in ovarian and other cancers, and its deletion can alter proliferation, apoptosis, and cisplatin sensitivity. This model permits exploration of autophagy-dependent survival mechanisms and synthetic lethal interactions, aiding identification of therapeutic vulnerabilities in autophagy-deficient tumors.
Typical applications include autophagy flux assays via LC3B and SQSTM1/p62 western blotting, cell viability and apoptosis tests for drug response, and colony formation studies. Immunofluorescence can visualize autophagosome accumulation, while co-immunoprecipitation maps Beclin 1 interacting partners. In vivo, these cells enable xenograft tumor growth studies to assess therapeutic responses. For further information, please contact Ascent Research.
